The latest updates to clinical guidelines on cholesterol represent a change of focus in cardiovascular preventionIt's no longer enough to look at a single number in a blood test; now the focus is on each person's overall risk and adapting medical decisions to that reality. This more nuanced approach encourages earlier treatment and sets more ambitious LDL cholesterol targets than in the past.
Behind these recommendations are decades of data that point in the same direction: The lower the LDL cholesterol level, the lower the likelihood of a heart attack or stroke.Leading scientific societies insist on combining lifestyle changes with appropriate use of drugs when needed, to reduce the enormous burden that cardiovascular diseases continue to have in Europe and the rest of the world.
A shift towards personalized cholesterol prevention
The new guidelines, led by entities such as the American College of Cardiology and the American Heart Association, and which also serve as a reference for Europe, advocate for a More personalized medicine in cholesterol managementThe idea is simple but powerful: not everyone faces the same risk, so it makes no sense to treat everyone with the same level of rigor.
Instead of focusing solely on the total cholesterol or LDL value, a set of factors is taken into account, including age, blood pressure, daily habits and medical historyas well as conditions such as diabetes, chronic inflammatory processes, or early menopause. Therefore, treatment is tailored to achieve the maximum possible protection against atherosclerotic cardiovascular disease.
This transition from a homogeneous approach to a more individualized one responds to a clear concern: despite the progress, Cardiovascular disease remains the leading cause of death globallyThe aging population, sedentary lifestyles, obesity, and diabetes continue to fuel the problem, making it clear that action is needed sooner and more effectively.
Experts emphasize that it's not about being stricter "just because," but about consistently applying the accumulated evidence: to reduce LDL cholesterol intensely and sustainably It is associated with a lower incidence of myocardial infarction, stroke, and other serious complications.
New LDL cholesterol targets based on risk
One of the most striking changes in the new guidelines is the adjustment of the acceptable LDL cholesterol levels, the so-called “bad cholesterol”. The goals become more demanding as the individual risk of suffering a cardiovascular event increases.
In people categorized as low or intermediate riskThe target is below 100 mg/dL of LDL cholesterol. In this group, if the cholesterol elevation is not very pronounced, lifestyle changes are often given the benefit of the doubt.
For those who consider themselves to be high cardiovascular risk (For example, patients with several accumulated risk factors or with certain chronic diseases), the goal becomes more stringent and is set at an LDL level below 70 mg/dL. Here, the combination of healthy habits and medication usually plays a more prominent role.
At the extreme are patients with history of heart attack, stroke or other cardiovascular eventsIn these cases, the proposed target is even lower: less than 55 mg/dL of LDL. The logic is clear: if the risk of them experiencing another event is very high, the protection must be maximum.
The guidelines also consider the possibility that, if these goals are not achieved with adequate doses of statins, additional therapies such as ezetimibe, bempedoic acid, or monoclonal antibodies against PCSK9These options are reserved for selected cases, but they reflect the extent to which there is an emphasis on not leaving cholesterol management halfway.
Tools for estimating risk: PREVENT-ASCVD
To tailor decisions to each individual, the new recommendations incorporate the PREVENT-ASCVD calculation tool, an updated model that allows estimate the risk of suffering a cardiovascular event in the next ten yearsAlthough it was developed in the United States, its risk-factor approach serves as a basis for similar strategies in Europe.
This calculator takes into account classic elements such as blood pressure, cholesterol, age, and smoking, but also includes “risk enhancers” such as a family history of early heart disease, diabetes, chronic inflammation, or certain hormonal characteristics, including early menopause.
A key advantage of this model over older estimates is that Avoid the tendency to overestimate riskwhich in previous calculations could reach between 40% and 50% in some people. By improving accuracy, both undertreatment and overmedication are avoided in truly low-risk profiles.
In clinical practice, the use of these calculators facilitates clearer dialogues between healthcare professionals and patients: seeing the estimated risk reflected as a specific percentage often helps to making shared decisions about lifestyle changes and drug usewith a more realistic plan adapted to each case.
The burden of cardiovascular diseases in Europe
Despite advances in diagnosis, treatment, and awareness campaigns, Atherosclerotic cardiovascular disease continues to be the leading cause of death worldwide.And Europe is no exception. Heart attacks, strokes, and other complications continue to generate an enormous health, social, and economic burden.
In many European countries, including Spain, an improvement in survival has been observed thanks to improved acute care and the use of effective drugsHowever, the number of people with risk factors continues to grow, driven by an increasingly sedentary lifestyle, excess weight, unhealthy diet, and the rise in diabetes.
Another point that experts highlight is the difficulty in maintaining long-term treatment goalsMany patients stop taking their medication, relax their dietary changes, or reduce their physical activity over time, which gradually diminishes the preventive effect.
Several cardiologists point out that, with current tools, it is estimated that More than 80% of cardiovascular diseases could be prevented If factors such as cholesterol, blood pressure, smoking, weight, and blood sugar were properly controlled, the challenge would be not only knowing what to do, but also ensuring its sustained application across the general population.
Healthy habits: the foundation of any strategy
The new guidelines insist that the first step in controlling cholesterol is not the pill, but the lifestyleMaintaining a balanced diet, exercising regularly, avoiding tobacco, getting enough sleep, and managing stress are essential pillars, both in Spain and in the rest of Europe.
In people with low or moderate riskThese changes may be enough to reach LDL cholesterol goals without medication. Even in those who do require medication, improving lifestyle habits helps reduce the necessary dosage, as other risk factors are also kept under control.
Experts emphasize that these recommendations are not a rigid and identical message for everyone, but a general guide that will then be followed. It must be adapted to the reality of each personAge, family and work circumstances, economic possibilities and individual preferences greatly influence which changes are realistic and sustainable.
In the European context, dietary patterns based on models such as the Mediterranean diet, rich in fruits, vegetables, legumes, olive oil, fish and nuts, which have been shown to reduce cardiovascular risk when followed consistently over the long term.
Diet and exercise in the control of LDL cholesterol
Diet has a direct impact on LDL cholesterol levels. Reducing the Saturated fats present in fatty meats, sausages, very fatty cheeses or fried foods It helps lower "bad" cholesterol, while choosing healthier fat sources contributes to improving the overall lipid profile.
The guidelines recommend prioritizing monounsaturated and polyunsaturated fatssuch as those found in virgin olive oil, oily fish, nuts, and other seeds. These fats can help lower LDL cholesterol and, in many cases, help maintain or even increase HDL cholesterol, known as "good cholesterol."
Another key component is the Soluble fiberThis type of fiber, found in fruits, legumes, oats, and many vegetables, facilitates the elimination of cholesterol through bile and helps lower blood cholesterol levels. Therefore, it is often included in dietary recommendations for heart health.
At the same time, regular physical exercise is considered one of the best allies for lipid control. Activities such as brisk walking, running, swimming, or cycling They lower LDL and triglycerides and, at the same time, tend to raise HDL levels, something especially valuable in people with cardiovascular risk.
The guidelines usually set as an objective at least 30 minutes of moderate physical activity most daysor approximately 20 minutes of more intense exercise about three times a week, always adapted to the age, physical condition, and any existing health conditions of each patient. Staying active also helps control weight, another factor closely linked to cholesterol.
Cholesterol-lowering medications: statins and beyond
When the combination of diet, exercise, and other lifestyle changes fails to achieve the set goals, the guidelines recommend to start drug treatment earlier than was done years agoThe idea is not to let time pass while cardiovascular risk continues to silently accumulate.
The Statins continue to be the mainstay in the treatment of LDL cholesterol. These medications have consistently demonstrated that they reduce the likelihood of heart attack, stroke, and other serious cardiovascular complications, both in primary prevention (before the first event) and in secondary prevention (in people who have already had problems).
Despite certain myths and misgivings that circulate, the available scientific evidence indicates that Statins are safe drugs for the vast majority of patients and that the benefits, in terms of risk reduction, far outweigh the potential adverse effects in the appropriate groups.
In cases where statins alone do not reduce LDL to the proposed targets, the guidelines consider adding other medications. Other treatments such as ezetimibe, bempedoic acid, or PCSK9 inhibitorsThese latter ones, based on monoclonal antibodies, are used mainly in very high-risk patients or those with difficult-to-control hypercholesterolemia.
Some experts also point out that keeping LDL below the classic "normal" values not only does not harm the brain or hormones, but could related to less cognitive decline in the long term. This type of data challenges the idea, still widespread in certain circles, that "a slightly high cholesterol isn't so bad."
A clearer roadmap for doctors and patients
The updated guidelines provide a a more defined roadmap for the management of dyslipidemiaIntegrating prevention, diagnosis, and treatment in a coherent manner reinforces the idea of acting as early and continuously as possible to reduce the burden of cardiovascular disease in the coming years.
The main message is that prevention cannot be based on a single figure, but on a overall risk assessment and tailored interventionsThis involves combining lifestyle changes, medication when necessary, and regular follow-up to adjust strategies as each person's circumstances change.
Cardiologists and scientific societies agree that the great challenge now is not so much defining what to do, but to ensure that these recommendations are received and implemented in daily practice. This involves strengthening health education, combating misinformation about treatments, and facilitating access to preventive care, both in primary care and cardiology.
With lower LDL cholesterol targets, more accurate risk calculation tools, and a renewed emphasis on personalized prevention, the new guidelines lay the foundation for a more proactive approach. For the population of Spain and the rest of Europe, this translates into a clear opportunity: to manage cholesterol in a more conscious and structured way to reduce the likelihood of suffering a heart attack or stroke in the future.